|
|
Press Releases
- 01.10.12:NW BIO TO PRESENT TODAY AT THE ONEMEDFORUM SF 2012 CONFERENCE
- 01.09.12:NW BIO REACHES 25 CLINICAL TRIAL SITES OPEN AND RECRUITING BY THE END OF Q4, 2011
- 12.19.11:NORTHWEST BIO REAFFIRMS ITS FREEDOM TO OPERATE; REFUTES OTHER PARTIES’ MISLEADING PATENT ASSERTIONS
- 12.02.11:NORTHWEST BIO IMPLEMENTS MAJOR BALANCE SHEET CLEAN-UP Removes $31.5 Million Of Liabilities
- 11.17.11:NORTHWEST BIO ANNOUNCES TRANSACTIONS FOR $5.4 MILLION IN NEW FINANCING
- 11.15.11:NORTHWEST BIO TO PRESENT AT SOCIETY OF NEURO-ONCOLOGY ANNUAL MEETING
- 11.01.11:NORTHWEST BIO ANNOUNCES INTERVIEW OF CEO LINDA POWERS IN TODAY'S CEO/CFO PUBLICATION
- 10.25.11:NORTHWEST BIO ANNOUNCES INITIATION OF S&P COVERAGE, WITH PUBLICATION OF FIRST COMPANY STOCK REPORT
- 10.06.11:NORTHWEST BIO ANNOUNCES POSITIVE THIRD QUARTER PROGRESS
- 10.04.11:NORTHWEST BIO WILL PRESENT AT THE SECOND ANNUAL "CANCER IMMUNOTHERAPY: A LONG AWAITED REALITY CONFERENCE" AT THE NEW YORK ACADEMY OF MEDICINE, OCTOBER 6, 2011
- 08.10.11:NWBT HIGHLIGHTS COST EFFECTIVENESS OF DCVAX® IN VIEW OF RECENT IMMUNOTHERAPY PRICING CONCERNS
- 08.04.11:NWBT ANNOUNCES FURTHER EXPANSION OF CLINCAL SITES IN ONGOING BRAIN CANCER TRIAL
- 07.08.11:Family Foundation of Business Leader Invests $4.55 Million In Northwest Biotherapeutics For Promising Clinical Trials In The US and Europe
- 06.08.11:Northwest Biotherapeutics Announces Change and Expansion of Management Team New CEO, COO, CSO and Senior VP Business Development
- 06.05.11:Northwest Biotherapeutics Announces Series of Financing Arrangements. $3 Million Initial Funding, and Up To $25 Million Further Funding On Fixed, Favorable Terms
- 05.25.11:NORTHWEST BIOTHERAPEUTICS FURTHER EXPANDS ONGOING BRAIN CANCER TRIAL
- 05.20.11:Northwest Biotherapeutics to Present at American Society of Cell and Gene Therapy
- 05.18.11:Northwest Biotherapeutics and the Fraunhofer Institute for Cell Therapy and Immunology Are Partnering for Clinical Trials and Compassionate Use Cases in Europe
- 05.03.11: NORTHWEST BIOTHERAPEUTICS’ ONGOING BRAIN CANCER TRIAL RECRUITING ADDITIONAL PATIENTS AT FOUR MEDICAL CENTERS ACROSS US
- 03.16.11: Northwest Biotherapeutics Addresses Recent Market Activity
- 02.14.11: Northwest Biotherapeutics to Present at BIO CEO & INVESTOR CONFERENCE
- 01.24.11: Northwest Biotherapeutics Resuming Enrollment In Promising 240-Patient Clinical Trial of DCVax® for Brain Cancer
- 11.04.10: Northwest Biotherapeutics Receives Two “Qualified Therapeutic Discovery Project” Grants
- 10.14.10: Northwest Biotherapeutics to Present at Inaugural Cancer Immunotherapy Conference
- 08.03.10: Long-Term Follow-Up of DCVax®-Treated Brain Cancer Patients Shows 33% of Patients Reached 4-Year Survival and 27% Have Reached or Exceeded 6-Year Survival
- 07.07.10: Northwest Biotherapeutics Raises Funding and Proceeds With Balance Sheet Restructuring
- 06.07.10: Exceptional Survival Data, Lower Costs Key To The Competitive Advantage Of DCVax® - Northwest Biotherapeutics’ Vaccine For Multiple Cancers
- 12.10.09: Northwest Biotherapeutics Announces Appointment of Robert A. Farmer to the Board of Directors
- 12.04.09: Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax® Manufacturing
- 10.21.09: Long-Term Data Updates Show Further Extensions of Survival and Delays in Recurrence In Brain Cancer Patients Who Received DCVax®-Brain
- 02.17.09: Update of Long-Term Data on Brain Cancer Patients Receiving DCVax®-Brain Continues to Show Striking Improvements in Delay of Disease and Survival
- 02.10.09: Northwest Biotherapeutics Secures $700,000 Equity Financing
- 01.09.09: Northwest Biotherapeutics Settles Class Action Complaint, and SEC Investigation Closed Without Action
- 12.23.08: Northwest Biotherapeutics Reports Encouraging Data On First Patients Who Have Completed Its Phase I/II Clinical Trial of DCVax-L In Metastatic Ovarian Cancer
- 12.23.08: Northwest Secures US$0.5 Million Debt Financing
- 11.06.08: Northwest Secures US$1.65 Million Debt Financing
- 10.02.08: Northwest Secures US$1.0 million Debt Financing
- 09.11.08: Long-Term Phase I and Phase I/II Trial Data Continue to Show Striking Improvement In Survival of Brain Cancer Patients Who Receive DCVax®-Brain
- 07.18.08: Northwest Biotherapeutics To present at Next Generation Vaccine Conference
- 05.06.08: Northwest secures US$4.0 million in debt financing
- 02.20.08: Phase I and Phase I/II DCVax®-Brain Data Continues to show Significantly Improved Survival Rates for Brain Cancer Patients
- 12.27.07: Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax®-L at University of Pennsylvania
- 12.20.07: Lonza Withdraws Majority of Claims In Patent Lawsuit Against Northwest Biotherapeutics
- 10.02.07: Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer
- 08.01.07: Northwest Biotherapeutics Disputes Patent Infringement Claims
- 07.16.07: Northwest Biotherapeutics, Inc. Responds to Media Reports
- 07.09.07: World’s First Therapeutic Vaccine for Brain Cancer Commercially Available to Patients in Switzerland
- 06.28.07: Northwest Biotherapeutics Announces Effectiveness of Reverse Stock Split
- 06.22.07: Northwest Biotherapeutics Announces Effectiveness Of Reverse Stock Split
- 06.22.07: Northwest Biotherapeutics Closes its Placement of Shares with Foreign Institutional Investors
- 06.18.07: Northwest Biotherapeutics Prices its Intended Placement of Shares with Foreign Institutional Investors
- 06.04.07: Northwest Biotherapeutics Initiates its Intended Placement of Shares with Foreign Institutional Investors
- 05.21.07: Northwest Biotherapeutics Intends to Place Shares with Foreign Institutional Investors
- 04.17.07: Northwest Biotherapeutics Files for Authorization for Use of DCVax®-Brain for Commercialization in Switzerland
- 03.08.07: Northwest Biotherapeutics, Inc. Appoints Chief Financial Officer
- 03.07.07: Northwest Biotherapeutics Adds UCLA As A Site To Its Pivotal Phase II Brain Cancer Trial
- 02.13.07: First Patients Undergo Surgery In Northwest Biotherapeutics’ Phase II Brain Cancer Trial
- 11.28.06: Northwest Biotherapeutics Receives Institutional Review Board Approval to Accrue Patients In Phase II Brain Cancer Trial
- 10.30.06: Northwest Biotherapeutics Discusses Results From Clinical Trials in Brain Cancer at Two Conferences
- 10.26.06: Northwest Biotherapeutics to Present at the 21st Annual Meeting of the International Society for Biological Therapy of Cancer
- 10.23.06: Northwest Biotherapeutics to Present at the CE Unterberg, Towbin Life Sciences Conference
- 09.07.06: Northwest Biotherapeutics Receives FDA Clearance For Lung Cancer Trial
- 08.28.06: Northwest Biotherapeutics Updates Brain Cancer Clinical Data
- 08.21.06: Northwest Biotherapeutics to Present Update on Brain Cancer Clinical Data at the Cambridge Healthtech Institute’s Cancer Immunotherapeutics and Vaccines Conference
- 08.16.06: Northwest Biotherapeutics to Present Data on CXCR4 at the Cambridge Healthtech Institute’s Targeted Cancer Therapies Conference
- 08.15.06: Northwest Biotherapeutics Signs Synteract for Management of Its DCVax®-Brain Cancer Phase II Clinical Trial
- 07.10.06: Northwest Biotherapeutics to Present at the CE Unterberg, Towbin Emerging Growth Conference
- 05.23.06: Northwest Biotherapeutics Updates Brain Cancer Clinical Data
- 04.06.06: Northwest Biotherapeutics to Present at BIO 2006 Business Forum
- 03.31.06: Northwest Biotherapeutics Announces $5.5 Million Private Placement of Common Stock and Warrants
- 02.22.06: Brain Cancer Patients Living Longer and Doing Better After Personalized Vaccine Therapy. Unprecedented Improvement in Survival Results in FDA Allowance of Booster Shots for Trial Participants
- 02.17.06: Northwest Biotherapeutics to Present New Data on CXCR4 at the Molecular Medicine Tri-Conference
- 09.22.05: Northwest Biotherapeutics to Present at the Williamsburg BioProcessing Foundation Conference
- 09.21.05: Northwest Biotherapeutics Announces Clinical Advisory Board for Brain Cancer Program
- 08.02.05: Northwest Biotherapeutics Announces Appointment of Paul Zeltzer, MD as Medical Director
- 06.01.05: Northwest Biotherapeutics, Inc. Brain Cancer Treatment to Undergo Broader Testing Based on Encouraging Phase I Clinical Trials
- 03.21.05: Northwest Biotherapeutics, Inc. Receives Patent Coverage for Antibodies to Primary and Metastatic Cancer Protein
- 01.31.05: Northwest Biotherapeutics, Inc. to Initiate Phase III Clinical Trial for Prostate Cancer
- 04.26.04: Northwest Biotherapeutics, Inc. Announces Recapitalization Agreement with Toucan Capital
- 02.18.04: Northwest Biotherapeutics, Inc. Accepts Resignation of Daniel O. Wilds, Chairman and Chief Executive Officer
- 10.23.03: Northwest Biotherapeutics Publishes Preclinical Data on DCVax®-Direct which Enhances Dendritic Cell Function and Immune Response
- 07.23.03: Northwest Biotherapeutics, Inc. to Present Favorable Data on Effects of DCVax®-Prostate on Progression of Advanced-Stage Prostate Cancer
- 07.07.03: Northwest Biotherapeutics' initial DCVax®-Direct clinical evaluation being planned at H. Lee Moffitt Cancer Center
- 06.25.03: Northwest Biotherapeutics identifies CXCR-4 clinical antibodies that inhibit tumor cell division and metastasis
- 06.20.03: Northwest Biotherapeutics, Inc. secures additional capital and reduces expenses
- 06.18.03: Northwest Biotherapeutics Presents New Data on its Approach for the Treatment of Solid Tumors
- 05.14.03: Northwest Biotherapeutics, Inc. Announces First-Quarter Financial Results
|
